ALEC
Price
$3.08
Change
+$0.13 (+4.41%)
Updated
Sep 18, 01:47 PM (EDT)
Capitalization
279.35M
54 days until earnings call
IDYA
Price
$25.41
Change
+$0.98 (+4.01%)
Updated
Sep 18, 12:52 PM (EDT)
Capitalization
2.17B
54 days until earnings call
Interact to see
Advertisement

ALEC vs IDYA

Header iconALEC vs IDYA Comparison
Open Charts ALEC vs IDYABanner chart's image
Alector
Price$3.08
Change+$0.13 (+4.41%)
Volume$4K
Capitalization279.35M
IDEAYA Biosciences
Price$25.41
Change+$0.98 (+4.01%)
Volume$100
Capitalization2.17B
ALEC vs IDYA Comparison Chart in %
Loading...
ALEC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALEC vs. IDYA commentary
Sep 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALEC is a StrongBuy and IDYA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 18, 2025
Stock price -- (ALEC: $2.94 vs. IDYA: $24.44)
Brand notoriety: ALEC and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALEC: 108% vs. IDYA: 61%
Market capitalization -- ALEC: $279.35M vs. IDYA: $2.17B
ALEC [@Biotechnology] is valued at $279.35M. IDYA’s [@Biotechnology] market capitalization is $2.17B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.34B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALEC’s FA Score shows that 0 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • ALEC’s FA Score: 0 green, 5 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, ALEC is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALEC’s TA Score shows that 4 TA indicator(s) are bullish while IDYA’s TA Score has 4 bullish TA indicator(s).

  • ALEC’s TA Score: 4 bullish, 5 bearish.
  • IDYA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both ALEC and IDYA are a bad buy in the short-term.

Price Growth

ALEC (@Biotechnology) experienced а +3.52% price change this week, while IDYA (@Biotechnology) price change was -1.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.22%. For the same industry, the average monthly price growth was +11.98%, and the average quarterly price growth was +38.97%.

Reported Earning Dates

ALEC is expected to report earnings on Nov 11, 2025.

IDYA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+2.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($2.17B) has a higher market cap than ALEC($279M). ALEC YTD gains are higher at: 55.556 vs. IDYA (-4.903). ALEC has higher annual earnings (EBITDA): -125.18M vs. IDYA (-380.2M). IDYA has more cash in the bank: 670M vs. ALEC (307M). IDYA has less debt than ALEC: IDYA (26.6M) vs ALEC (39.5M). ALEC has higher revenues than IDYA: ALEC (81.1M) vs IDYA (7M).
ALECIDYAALEC / IDYA
Capitalization279M2.17B13%
EBITDA-125.18M-380.2M33%
Gain YTD55.556-4.903-1,133%
P/E RatioN/AN/A-
Revenue81.1M7M1,159%
Total Cash307M670M46%
Total Debt39.5M26.6M148%
FUNDAMENTALS RATINGS
ALEC vs IDYA: Fundamental Ratings
ALEC
IDYA
OUTLOOK RATING
1..100
1418
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
60
Fair valued
PROFIT vs RISK RATING
1..100
10071
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
3752
P/E GROWTH RATING
1..100
93100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALEC's Valuation (55) in the Biotechnology industry is in the same range as IDYA (60) in the null industry. This means that ALEC’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's Profit vs Risk Rating (71) in the null industry is in the same range as ALEC (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to ALEC’s over the last 12 months.

IDYA's SMR Rating (97) in the null industry is in the same range as ALEC (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to ALEC’s over the last 12 months.

ALEC's Price Growth Rating (37) in the Biotechnology industry is in the same range as IDYA (52) in the null industry. This means that ALEC’s stock grew similarly to IDYA’s over the last 12 months.

ALEC's P/E Growth Rating (93) in the Biotechnology industry is in the same range as IDYA (100) in the null industry. This means that ALEC’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALECIDYA
RSI
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
61%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
79%
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 8 days ago
82%
Bullish Trend 14 days ago
77%
Declines
ODDS (%)
Bearish Trend 21 days ago
87%
Bearish Trend 4 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
69%
Aroon
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
ALEC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PEQIX25.38N/A
N/A
Victory Pioneer Equity Income A
PDARX12.21N/A
N/A
Principal Diversified Real Asset R6
IJEMX12.84N/A
N/A
VY® JPMorgan Emerging Markets Equity I
ARCHX19.24N/A
N/A
Archer Balanced
MLRMX10.14-0.03
-0.29%
NYLI Winslow Large Cap Growth SIMPLE Cl

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-1.13%
IMNM - IDYA
61%
Loosely correlated
-1.21%
SYRE - IDYA
59%
Loosely correlated
+1.82%
NRIX - IDYA
57%
Loosely correlated
+1.54%
CGON - IDYA
57%
Loosely correlated
+5.48%
XENE - IDYA
57%
Loosely correlated
+2.86%
More